Olaratumab (Lartruvo)

OFFICE ADMINISTRATION

FDA Approved Indication:
  • Indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery
Patients must meet the following criteria for the indication above:
  • Prescribed by an oncologist, AND
  • Patient is at least 18 years of age, AND
  • Medical record documenation confirms diagnosis of soft tissue sarcoma with a histologic subtype for which an anthracyline-containing regimen is appropriate and not amenable to curative treatment with surgery or radiotherapy, AND
  • Lartruvo will be administered with doxorubicin for the first 8 cycles
Dosing:
  • 15 mg/kg as an intravenous infusion over 60 minutes on Days 1 and 8 of each 21-day cycle
  • For the first 8 cycles, Lartruvo is administered with doxorubicin
  • Premedicate with diphenhydramine and dexamethasone IV, prior to Lartruvo on Day 1 of cycle 1

Approval:

  • One year

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar